Abstract Number: 937 • 2019 ACR/ARP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study
Background/Purpose: The monoclonal antibody bimekizumab potently and selectively neutralizes both IL-17A and IL-17F. We report the 48-week efficacy and safety of bimekizumab in patients (pts)…Abstract Number: 1536 • 2019 ACR/ARP Annual Meeting
A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Background/Purpose: Post-transcriptional control of cytokine and chemokine gene expression is an important checkpoint during inflammation. The MAPKAPK2 (MK2) pathway in particular is critical in regulating…Abstract Number: 598 • 2019 ACR/ARP Annual Meeting
Identification of Potential Risk Factors for Spinal Structural Damage in Chinese Patients with Ankylosing Spondylitis
Background/Purpose: Spinal structural damage can lead to physical dysfunction and decline of spinal mobility in patients with ankylosing spondylitis (AS). Although great progress has been…Abstract Number: 1010 • 2019 ACR/ARP Annual Meeting
IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis
Background/Purpose: Ankylosing spondylitis (AS) is associated with entheseal inflammation and new bone formation. Resident populations of lymphocytes have been identified at the enthesis that on…Abstract Number: 1542 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trial and usually varies over time. The purpose…Abstract Number: 603 • 2019 ACR/ARP Annual Meeting
Are the Modified New York and ASAS Criteria Interchangeable in the Classification of Patients with Spondyloarthritis with Radiographic Sacroiliitis?
Background/Purpose: Patients with axial spondyloarthritis (axSpA) with radiographic sacroiliitis may be classified using the modified New York (mNY) criteria as ankylosing spondylitis and using the…Abstract Number: 1082 • 2019 ACR/ARP Annual Meeting
Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea
Background/Purpose: The aim of this study is to determine the risk of overall malignancy and site-specific cancer in ankylosing spondylitis (AS) patients compared with patients…Abstract Number: 1544 • 2019 ACR/ARP Annual Meeting
Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled ankylosing spondylitis (AS) (radiographic axial SpA) patients treated with subcutaneous…Abstract Number: 608 • 2019 ACR/ARP Annual Meeting
Prevalence of Radiographic Entheseal Lesions at the Hip and Pelvic Region in Patients with Ankylosing Spondylitis versus Controls
Background/Purpose: Enthesitis is one of the features of ankylosing spondylitis (AS). High prevalence of structural and inflammatory ultrasound lesions of peripheral entheses are found in…Abstract Number: 1087 • 2019 ACR/ARP Annual Meeting
Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)
Background/Purpose: Golimumab (GLM) has shown its efficacy and tolerability in various randomized clinical trials. Systemic data for GLM regarding health-economic parameters in daily clinical practice…Abstract Number: 1551 • 2019 ACR/ARP Annual Meeting
Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with axial spondyloarthritis (axSpA), but still some patients switch to a different TNFi because of…Abstract Number: 611 • 2019 ACR/ARP Annual Meeting
Retina of Ankylosing Spondylitis Patients Shows Early Signs of Atherosclerotic Disease in Comparison with Healthy Controls
Background/Purpose: Chronic systemic inflammation in patients with ankylosing spondylitis (AS) contributes to the development of cardiovascular disease (CVD). Early recognition of microvascular changes could improve…Abstract Number: 1109 • 2019 ACR/ARP Annual Meeting
Development of Smart-phone Spondyloarthritis Management System and Real-world Study of Chinese Patients with Ankylosing Spondylitis
Background/Purpose: We developed a multipurpose digital platform, Smart-phone SpondyloArthritis Management System (SpAMS), based on two of the most important objectives: 1) for patients: to activate…Abstract Number: 1777 • 2019 ACR/ARP Annual Meeting
The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis
Background/Purpose: Interleukin 12 (IL-12) and 23 (IL-23) may play a pivotal role in the pathogenesis of inflammatory diseases, including Spondyloarthritis (SpA). In mice, the deubiquitinase…Abstract Number: 434 • 2019 ACR/ARP Annual Meeting
Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials
Background/Purpose: Previous trials have used the Short Form (SF)-36 questionnaire to evaluate the impact of ankylosing spondylitis/radiographic axial spondyloarthritis (AS/r-axSpA) on health-related quality of life…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 62
- Next Page »